The DCCA is out with report describing inefficient comp. Could be a drag for Tryg and ALMB despite the industry objections. ALMB drop looks attractive, but it could drag on for two more years.
Adj PTP +1%/+9% (ABG/cons) driven by UW as financials miss; DPS just soft, SBB likely to be announced in connection with AGM; Cons 25e-26e (+0-2%) underl. UW; stock follow up 1-2%
Q4e: Sampo CR of 85% and adj. PTP of EUR 380m; Adj. EPS '24e -1% (Hastings) and '25e +3% (financials); A great franchise at an unwarranted discount: BUY
Q3e: group CR of 83.7% and group adj PTP of EUR 464m. Adj. EPS '24e +2% and '25e-'26e -4% (mainly int. rate-driven). We argue that its UW skills deserve a premium valuation: BUY.
High price increases in non-life = margin expansion; Attractive dividend levels to come from life units; BUY stability from Sampo/Tryg; earnings growth STB/GJF
Underlying and reported UW in line, while financials beat. Adj. EPS up 1% for '25e-'26e, while '24e up by 7% from the beat. Cap. adj. P/E in '26e at 11x (15% discount to peers) and yield of ~23%.
If P&C's underlying CR +5% vs ABG, and much better financials. Reported CR (If P&C) a tad better at 83.1% (fire in DK). Cons.24e (+2-4% amid financials), 25e-26e (+1%); stock just up